B3A2 Polyclonal Antibody

alternative products:Additional isoforms seem to exist,Plasma membrane anion exchange protein of wide distribution.,Belongs to the anion exchanger (TC 2.A.31) family.,

The B3A2 Polyclonal Antibody is a meticulously crafted and highly specific immunological tool designed to facilitate accurate detection and analysis of the BCR-ABL1 fusion protein. This antibody is produced through a rigorous process, ensuring exceptional quality and reliability in its performance.

With its polyclonal nature, this antibody exhibits a broad range of binding affinities, enabling it to recognize multiple epitopes on the BCR-ABL1 fusion protein. This characteristic enhances its versatility and effectiveness in various experimental applications, including Western blotting, immunoprecipitation, and immunohistochemistry.

The B3A2 Polyclonal Antibody demonstrates exceptional sensitivity and specificity, enabling precise identification and quantification of the BCR-ABL1 fusion protein. Its robust performance ensures reliable and reproducible results, making it an indispensable tool for researchers and clinicians alike.

Furthermore, this antibody is meticulously validated to ensure its consistent performance across different sample types and experimental conditions. Its high affinity and low background noise contribute to the generation of accurate and reliable data, facilitating insightful analysis and interpretation.

The B3A2 Polyclonal Antibody is supplied in a convenient and user-friendly format, allowing for easy handling and storage. It is provided in a ready-to-use solution, eliminating the need for time-consuming preparation steps. Additionally, it is available in various sizes to accommodate different experimental requirements.

In summary, the B3A2 Polyclonal Antibody is a meticulously developed and extensively validated immunological tool that offers exceptional sensitivity, specificity, and versatility. Its reliable performance and user-friendly format make it an invaluable asset for researchers and clinicians seeking to unravel the complexities of the BCR-ABL1 fusion protein and its implications in various diseases.